Vivoryon Therapeutics Statistics

Total Valuation

Vivoryon Therapeutics has a market cap or net worth of EUR 54.74 million. The enterprise value is 26.20 million.

Market Cap	54.74M
Enterprise Value	26.20M

Important Dates

The next estimated earnings date is Friday, September 13, 2024.

Earnings Date	Sep 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Vivoryon Therapeutics has 26.07 million shares outstanding.

Shares Outstanding	26.07M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	11.57%
Owned by Institutions (%)	24.74%
Float	21.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	-14.64
PB Ratio	2.08
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.92
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.22

Financial Position

The company has a current ratio of 9.37, with a Debt / Equity ratio of 0.14.

Current Ratio	9.37
Quick Ratio	9.30
Debt / Equity	0.14
Debt / EBITDA	n/a
Debt / FCF	-0.00
Interest Coverage	-504.23

Financial Efficiency

Return on equity (ROE) is -107.38% and return on invested capital (ROIC) is -66.65%.

Return on Equity (ROE)	-107.38%
Return on Assets (ROA)	-56.74%
Return on Capital (ROIC)	-66.65%
Revenue Per Employee	-241,333
Profits Per Employee	-1.89M
Employee Count	15
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -83.44% in the last 52 weeks. The beta is 1.88, so Vivoryon Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.88
52-Week Price Change	-83.44%
50-Day Moving Average	2.18
200-Day Moving Average	3.91
Relative Strength Index (RSI)	46.32
Average Volume (20 Days)	85,187

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Vivoryon Therapeutics had revenue of EUR -3.62 million and -28.34 million in losses. Loss per share was -1.12.

Revenue	-3.62M
Gross Profit	-3.10M
Operating Income	-28.24M
Pretax Income	-28.58M
Net Income	-28.34M
EBITDA	-28.16M
EBIT	-28.24M
Loss Per Share	-1.12

Balance Sheet

The company has 28.58 million in cash and 38,000 in debt, giving a net cash position of 28.55 million or 1.10 per share.

Cash & Cash Equivalents	28.58M
Total Debt	38,000
Net Cash	28.55M
Net Cash Per Share	1.10
Equity (Book Value)	26.28M
Book Value Per Share	1.01
Working Capital	26.63M

Cash Flow

In the last 12 months, operating cash flow was -21.54 million and capital expenditures -14,000, giving a free cash flow of -21.56 million.

Operating Cash Flow	-21.54M
Capital Expenditures	-14,000
Free Cash Flow	-21.56M
FCF Per Share	-0.83

Margins

Gross Margin	n/a
Operating Margin	780.03%
Pretax Margin	789.39%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	595.44%

Dividends & Yields

Vivoryon Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-53.47%
FCF Yield	-39.38%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a